Abstract
It is well established that both estrogen loss and type II diabetes mellitus (DMII) can impair bone metabolism, but whether estrogen loss exacerbates the effects of DMII is unclear. Therefore, we determined if ovariectomy (OVX) of rats on a long-term high-fat/sugar diet and injection of a low dose of streptozotocin (DMII) decreased bone mineral density (BMD) more than OVX or DMII alone. Bone insulin signaling is known to support bone metabolism; therefore, we also tested the hypothesis that OVX DMII rats (DOVX) would exhibit greater reductions in the expression of proteins important in insulin signaling, including IRS-1, IRS-2, and IGF-1. As hypothesized, BMD and plasma estrogen levels were decreased more in DOVX rats than in rats following OVX (NOVX) or DMII (DS) alone. IGF-1 expression was decreased in the liver, kidney, skeletal muscle, and bone of DOVX, DS, and NOVX rats; however, the decrease was larger and occurred sooner in DOVX rats. While IRS-1 and IRS-2 decreased in most groups in all tissues examined, the expression patterns differed in both a group- and tissue-dependent fashion. In conclusion, these data demonstrate that estrogen loss and DMII induced by a high-fat/sugar diet interact to produce osteoporosis and support the hypothesis that the bone loss may be mediated at least in part by concurrent decreases in the insulin signaling proteins in bone.
Similar content being viewed by others
References
M. Prasannarong, K. Vichaiwong, V. Saengsirisuwan, Calorie restriction prevents the development of insulin resistance and impaired insulin signaling in skeletal muscle of ovariectomized rats. Biochim. Biophys. Acta 1822, 1051–1061 (2012)
D. Unal, S. Aksak, Z. Halici, O. Sengul, B. Polat, B. Unal, M. Halici, Effects of diabetes mellitus on the rat liver during the postmenopausal period. J. Mol. Histol. 42, 273–287 (2011)
H. Chang-Quan, D. Bi-Rong, H. Ping, L. Zhen-Chan, Insufficient renal 1-alpha hydroxylase and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus. J. Bone. Miner. Metab. 26, 561–568 (2008)
S. Elis, H.W. Courtland, Y. Wu, J.C. Fritton, H. Sun, C.J. Rosen, S. Yakar, Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J. Bone. Miner. Res. 25, 2051–2058 (2010)
R. Blakytny, M. Spraul, E.B. Jude, Review: the diabetic bone: a cellular and molecular perspective. Int. J. Low. Extrem. Wounds 10, 16–32 (2011)
T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377, 1276–1287 (2011)
G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)
F.J. de Paula, M.C. Horowitz, C.J. Rosen, Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26, 622–630 (2010)
S. Kurra, E. Siris, Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab. Res. Rev. 27, 430–435 (2011)
C. Torti, G. Mazziotti, P.A. Soldini, E. Focà, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)
S. Perrini, A. Natalicchio, L. Laviola, A. Cignarelli, M. Melchiorre, F. De Stefano, C. Caccioppoli, A. Leonardini, S. Martemucci, G. Belsanti, S. Miccoli, A. Ciampolillo, A. Corrado, F.P. Cantatore, R. Giorgino, F. Giorgino, Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 149, 1302–1313 (2008)
A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)
J. Paccou, J. Dewailly, B. Cortet, Reduced levels of serum IGF-1 is related to the presence of osteoporotic fractures in male idiopathic osteoporosis. Joint Bone Spine 79, 78–82 (2012)
J. Vangipurapu, A. Stančáková, T. Kuulasmaa, P. Soininen, A.J. Kangas, M. Ala-Korpela, J. Kuusisto, M. Laakso, Association between liver insulin resistance and cardiovascular risk factors. J. Intern. Med. (2012). doi:10.1111/j.1365-2796.2012.02540.x
R.A. Soslow, A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, A.T. Koki, COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89, 2637–2645 (2000)
R.R. Bosch, S.W. Janssen, P.N. Span, A. Olthaar, S.E. van Emst-de Vries, P.H. Willems, J.M.G. Martens, A.R. Hermus, C.C. Sweep, Exploring levels of hexosamine biosynthesis pathway intermediates and protein kinase C isoforms in muscle and fat tissue of Zucker diabetic fatty rats. Endocrine 20, 247–252 (2003)
M. Mansour, D. White, C. Wernette, J. Dennis, Y.X. Tao, R. Collins, L. Parker, E. Morrison, Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor. Endocrine 37, 220–230 (2010)
M.H. Giroix, K. Louchami, Y.A. Carpentier, A. Sener, W.J. Malaisse, Fatty acid pattern of pancreatic islet lipids in Goto–Kakizaki rats. Endocrine 37, 173–179 (2010)
M. Matsushita, K. Tamura, S. Osada, H. Kogo, Effect of troglitazone on the excess testosterone and LH secretion in thyroidectomized, insulin-resistant, type 2 diabetic Goto–Kakizaki rats. Endocrine 27, 301–305 (2005)
M.S. Islam, T. Loots du, Experimental rodent models of type 2 diabetes: a review. Methods Find. Exp. Clin. Pharmacol. 31, 249–261 (2009)
M. Yu, W. Zhou, Y. Song, F. Yu, D. Li, S. Na, G. Zou, M. Zhai, C. Xie, Development of mesenchymal stem cell-implant complexes by cultured cells sheet enhances osseointegration in type 2 diabetic rat model. Bone 49, 387–394 (2011)
K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, P. Ramarao, Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313–320 (2005)
M.J. Reed, K. Meszaros, L.J. Entes, M.D. Claypool, J.G. Pinkett, T.M. Gadbois, G.M. Reaven, A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390–1394 (2000)
W. Sun, Y. Bi, H. Liang, M. Cai, X. Chen, Y. Zhu, M. Li, F. Xu, Q. Yu, X. He, J. Ye, J. Weng, Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine 39, 235–241 (2011)
D. Merlotti, L. Gennari, F. Dotta, D. Lauro, R. Nuti, Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 20, 683–690 (2010)
R.A. Kayal, J. Alblowi, E. McKenzie, N. Krothapalli, L. Silkman, L. Gerstenfeld, T.A. Einhorn, D.T. Graves, Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone 44, 357–363 (2009)
A. Montagnani, S. Gonnelli, M. Alessandri, R. Nuti, Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin. Exp. Res. 23, 84–90 (2011)
J.M. Pritchard, L.M. Giangregorio, S.A. Atkinson, K.A. Beattie, D. Inglis, G. Ioannidis, Z. Punthakee, J.D. Adachi, A. Papaioannou, Adults with type 2 diabetes mellitus (DM) have an elevated fracture risk despite normal areal bone mineral density (aBMD). Arthr. Care Res. (Hoboken) 64, 83–91 (2012)
T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784–788 (2009)
G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40, 102–108 (2011)
A. Shu, M.T. Yin, E. Stein, S. Cremers, E. Dworakowski, R. Ives, M.R. Rubin, Bone structure and turnover in type 2 diabetes mellitus. Osteoporos. Int. 23, 635–641 (2012)
C. Hamann, C. Goettsch, J. Mettelsiefen, V. Henkenjohann, M. Rauner, U. Hempel, R. Bernhardt, N. Fratzl-Zelman, P. Roschger, S. Rammelt, K.P. Günther, L.C. Hofbauer, Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am. J. Physiol. Endocrinol. Metab. 301, E1220–E1228 (2011)
N. Erdal, S. Gürgül, S. Kavak, A. Yildiz, M. Emre, Deterioration of bone quality by streptozotocin (STZ)-induced type 2 diabetes mellitus in rats. Biol. Trace Elem. Res. 140, 342–353 (2011)
S. Chakreeyarat, S. Saetung, L.O. Chailurkit, S. Rattanasiri, S. Ditbanjong, N. Chitrapazt, S. Jaovisidha, B. Ongphiphadhanakul, Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes. Endocrine 39, 278–282 (2011)
M. Yamamoto, T. Yamaguchi, K. Nawata, M. Yamauchi, T. Sugimoto, Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 1277–1284 (2012)
L. Sauque-Reyna, M.A. Salcedo-Parra, P.R. Sánchez-Vargas, J.D. Flores-Helguera, C. Badillo-Sánchez, A. Reza-Albarrán, M. Rodríguez-Morán, F. Guerrero-Romero, Bone mineral density in patients with type 2 diabetes. Rev. Invest. Clin. 63, 162–169 (2011)
S. Arikan, A. Tuzcu, M. Bahceci, S. Ozmen, D. Gokalp, Insulin resistance in type 2 diabetes mellitus may be related to bone mineral density. J. Clin. Densitom. 15, 186–190 (2012)
N. Ogata, H. Kawaguchi, Involvement of insulin and IGF-1 signaling molecules in bone metabolism. Clin. Calcium 18, 614–622 (2008)
T. Akune, N. Ogata, K. Hoshi, N. Kubota, Y. Terauchi, K. Tobe, H. Takagi, Y. Azuma, T. Kadowaki, K. Nakamura, H. Kawaguchi, Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J. Cell. Biol. 159, 147–156 (2002)
W. Zhang, X. Shen, C. Wan, Q. Zhao, L. Zhang, Q. Zhou, L. Deng, Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell. Biochem. Funct. 30, 297–302 (2012)
M. Cipok, S. Aga-Mizrachi, A. Bak, T. Feurstein, R. Steinhart, C. Brodie, S.R. Sampson, Protein kinase Calpha regulates insulin receptor signaling in skeletal muscle. Biochem. Biophys. Res. Commun. 345, 817–824 (2006)
M.K. Diamond-Stanic, E.M. Marchionne, Critical role of the transient activation of p38 MAPK in the etiology of skeletal muscle insulin resistance induced by low-level in vitro oxidant stress. Biochem. Biophys. Res. Commun. 405, 439–444 (2011)
Y. Segev, R. Eshet, O. Yakir, N. Haim, M. Phillip, D. Landau, Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes. Diabetologia 50, 1327–1334 (2007)
J.L. Bailey, B. Zheng, Z. Hu, S.R. Price, W.E. Mitch, Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J. Am. Soc. Nephrol. 17, 1388–1394 (2006)
V.T. Samuel, G.I. Shulman, Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012)
Y. Zhang, B. Zhou, F. Zhang, J. Wu, Y. Hu, Y. Liu, Q. Zhai, Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61, 1434–1443 (2012)
O.T. Hardy, M.P. Czech, S. Corvera, What causes the insulin resistance underlying obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19, 81–87 (2012)
A.R. Martins, R.T. Nachbar, R. Gorjao, M.A. Vinolo, W.T. Festuccia, R.H. Lambertucci, M.F. Cury-Boaventura, L.R. Silveira, R. Curi, S.M. Hirabara, Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 11, 30 (2012)
S.S. Moon, Y.S. Lee, S.W. Kim, Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine (2012). doi:10.1007/s12020-012-9639-6
D.C. Leitman, S. Paruthiyil, C. Yuan, C.B. Herber, M. Olshansky, M. Tagliaferri, I. Cohen, T.P. Speed, Tissue-specific regulation of genes by estrogen receptors. Semin. Reprod. Med. 30, 14–22 (2012)
A. Margoni, L. Fotis, A.G. Papavassiliou, The transforming growth factor-beta/bone morphogenetic protein signalling pathway in adipogenesis. Int. J. Biochem. Cell. Biol. 44, 475–479 (2012)
P. Magni, E. Dozio, E. Galliera, M. Ruscica, M.M. Corsi, Molecular aspects of adipokine-bone interactions. Curr. Mol. Med. 10, 522–532 (2010)
Acknowledgments
We thank Professor Virginia L. Brooks for editing the language (Department of Physiology and Pharmacology, Oregon Health & Science University, Portland, Oregon 97239, USA. brooksv@ohsu.edu). This study was financially supported by Hebei Natural Science Foundation (C2009001179).
Conflict of interest
None of the authors has any conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, B., Wang, Y., Liu, Y. et al. Altered gene expression involved in insulin signaling pathway in type II diabetic osteoporosis rats model. Endocrine 43, 136–146 (2013). https://doi.org/10.1007/s12020-012-9757-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-012-9757-1